Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of SCCHN~* Recurrent and/or metastatic SCCHN, not suitable for local-regional treatment~* Presence of at least 1 measurable lesion according to RECIST Version 1.1~* Signed written informed consent before any trial-related activities are carried out~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Other protocol-defined inclusion criteria could apply~Exclusion Criteria:~* Prior systemic chemotherapy, except if given as part of multimodal treatment for locally advanced disease, that was completed within 6 months before randomization~* Surgery (excluding prior biopsy for diagnosis) or irradiation within 4 weeks before trial entry~* Previous treatment with monoclonal antibody or signal transduction inhibitors targeting epidermal growth factor receptor~* Nasopharyngeal carcinoma~* Known central nervous system metastasis and/or leptomeningeal disease~* Medical or psychological condition that would not permit the participant to complete the trial or sign informed consent~* Legal incapacity or limited legal capacity~* Other protocol-defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (Type: EXPERIMENTAL): None
- Cisplatin/Carboplatin + 5-Flurouracil (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).